CancerWorld shared a post on LinkedIn:
“Five trials. Five cancers. One standing ovation. But what did ASCO 2026 really promise patients?
From prostate cancer and dedifferentiated liposarcoma to RET-positive lung cancer, advanced squamous lung cancer, and metastatic pancreatic cancer, this year’s ASCO plenary showcased five landmark studies that could reshape oncology.
Yet beyond the applause lies a more difficult question: How long will it take for thesebreakthroughs to reach the patients who need them most?
This feature goes beyond the headlines, examining not only the science behind each trial, but also the challenges of access, biomarker testing, reimbursement, and implementation that will ultimately determine their real-world impact.”
Other articles about CancerWorld on OncoDaily.